title: Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment.
authors.affiliation: Department of Internal Medicine 3, Center of Integrated Oncology (CIO) Cologne-Bonn, University Hospital of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany, georg.feldmann@uni-bonn.de.
authors.forename: Georg
authors.initials: G
authors.lastname: Feldmann
authors.forename: Peter
authors.initials: P
authors.lastname: Brossart
authors.forename: Marie
authors.initials: M
authors.lastname: von Lilienfeld-Toal
mesh_terms: D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D001374:Azacitidine / Q000009:adverse effects*; D006801:Humans; D007964:Leukocytosis / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine